Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LJPC-501 in Pediatric CRH
NCT03623529Phase 2Unknown
- Sponsor
- La Jolla Pharmaceutical Company
- Start
- Aug 2018
- Primary completion
- Mar 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of Angiotensin II in Catecholamine-resistant hypotension, Distributive shock (DS), sponsored by La Jolla Pharmaceutical Company. Status: unknown.
02
Drugs
Angiotensin II
03
Conditions
Catecholamine-resistant hypotensionDistributive shock (DS)
Beyond the preview
Go deeper on NCT03623529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03623529.